Sep 5, 2018   SOURCE: PR NewsWire

Global Bipolar Disorder Disease Market 2018-2024 - Otsuka initiates Phase III Development of Rexulti for Bipolar Mania Without Proof-of-Concept Trial

DUBLIN, Sept. 5, 2018 /PRNewswire/ --

The "Bipolar Disorder Disease Coverage to 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bipolar disorder is a psychiatric disorder characterized by unusual shifts in mood, energy, activity levels, and the ability to carry out everyday tasks. Patients with the disorder may experience periods of mania (an overly joyful or overexcited state) followed by periods of depression (feelings of extreme sadness or hopelessness). Symptoms of bipolar disorder are severe and can result in damaged relationships, poor educational or occupational performance, and even suicide.

Market Snapshot

    --  Temporary downturn in bipolar market value will be recouped by oral drug
        approvals/launches and sales momentum of LAIs.
    --  The complexity of bipolar disorder is yet to be unlocked, contributing
        to a lack of episode-tailored treatment strategies.
    --  Forecasted growth in the total prevalence of bipolar I disorder and
        bipolar II disorder will be driven by demographics.
    --  New brand Vraylar is yet to distinguish itself, but its long patent life
        permits ample time to improve product positioning.
    --  Otsuka initiates Phase III development of Rexulti for bipolar mania
        without proof-of-concept trial.

Key Topics Covered:

Forecast: Bipolar Disorder 

    --  Abilify (Aripiprazole)
    --  Abilify Maintena (Aripiprazole)
    --  Geodon (Ziprasidone)
    --  Lamictal/Lamictal Xr (Lamotrigine)
    --  Latuda (Lurasidone)
    --  Lumateperone
    --  Risperdal Consta (Risperidone)
    --  Saphris (Asenapine)
    --  Seroquel/Seroquel Xr (Quetiapine)
    --  Vraylar (Cariprazine)
    --  Zyprexa (Olanzapine)

Treatment: Bipolar Disorder 

    --  Primary Research Methodology
    --  Disease Definition And Diagnosis
    --  Patient Segmentation
    --  Current Treatment Options
    --  Treatment Dynamics
    --  Unmet Needs In Bipolar Disorder

Epidemiology: Bipolar Disorder In The US, Japan, And 5EU

    --  Disease Background
    --  Sources And Methodology
    --  Forecast: Bipolar I Disorder
    --  Forecast: Bipolar Ii Disorder
    --  Epidemiologist Insight
    --  Strengths And Limitations

Marketed Drugs: Bipolar Disorder 

    --  Product Profile: Abilify
    --  Product Profile: Abilify Maintena
    --  Product Profile: Geodon
    --  Product Profile: Lamictal
    --  Product Profile: Latuda
    --  Product Profile: Risperdal Consta
    --  Product Profile: Saphris
    --  Product Profile: Seroquel/Seroquel Xr
    --  Product Profile: Vraylar
    --  Product Profile: Zyprexa

Pipeline: Bipolar Disorder

    --  Clinical Pipeline Overview
    --  Product Profile (Late Stage): Alks 3831
    --  Product Profile (Late Stage): Rexulti
    --  Product Profile (Late Stage): Lumateperone

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/79br4s/global_bipolar?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content with multimedia:http://www.prnewswire.com/news-releases/global-bipolar-disorder-disease-market-2018-2024---otsuka-initiates-phase-iii-development-of-rexulti-for-bipolar-mania-without-proof-of-concept-trial-300707068.html

SOURCE Research and Markets